Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Boehringer Ingelheim
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,504,509

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,504,509 protect, and when does it expire?

Patent 7,504,509 protects ZELBORAF and is included in one NDA.

This patent has fourteen patent family members in thirteen countries.

Summary for Patent: 7,504,509
Title:Compounds and methods for development of Ret modulators
Abstract: Compounds active on Ret are described, as well as methods of using such compounds. Also described are crystal structures of Ret surrogates that were determined using X-ray crystallography. The use of such Ret surrogate crystals and structural information can, for example, be used for identifying molecular scaffolds and for developing ligands that bind to and modulate Ret and for identifying improved ligands based on known ligands.
Inventor(s): Ibrahim; Prabha (Mountain View, CA), Artis; Dean Richard (Kensington, CA), Bremer; Ryan (Albany, CA), Habets; Gaston (Pleasant Hill, CA), Hurt; Clarence R. (San Ramon, CA), Mamo; Shumeye (Oakland, CA), Nespi; Marika (Berkeley, CA), Zhang; Chao (Moraga, CA), Zhang; Jiazhong (Oakland, CA), Zhu; Yong (Union City, CA), Zuckerman; Rebecca (Alameda, CA), Krupka; Heike (Hayward, CA), Kumar; Abhinav (Pleasant Hill, CA), West; Brian (San Francisco, CA)
Assignee: Plexxikon, Inc. (Berkley, CA)
Application Number:11/016,350
Patent Claim Types:
see list of patent claims
Compound; Composition; Device;

Drugs Protected by US Patent 7,504,509

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Hoffmann La Roche ZELBORAF vemurafenib TABLET;ORAL 202429-001 Aug 17, 2011 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
AstraZeneca
McKinsey
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.